

11 February 2026

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Optimer® Technology in Newly Launched Library Prep Kit

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that Twist Bioscience Corporation has launched its new TrueAmp Library Preparation Kit, which uses Aptamer's proprietary Optimer® binders as an enabling technology for stability at room temperature, within the TrueAmp Library Preparation Kit¹.

Product Launch

The TrueAmp Library Preparation Kit represents a significant advancement in next-generation sequencing (NGS) library amplification workflows. By using Aptamer's Optimer® binders, the Twist TrueAmp Library Prep Kit delivers a new level of exceptional performance to Twist's library preparation portfolio. These advantages are enabled by Twist's in-house developed enzymes, including a previously developed ligase and a newly developed polymerase.

Engineered for NGS applications, the specialised TrueAmp polymerase maximises coverage across typically hard-to-sequence regions of the genome - while maintaining high accuracy during DNA copying. The kit delivers high yields even from low-input or degraded starting samples, which minimises amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep Kit has been validated with the Twist HT-UDI adapter system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing.

Partnership Background

As announced in December 2025,² Aptamer issued a non-exclusive license to Twist Bioscience for the use of the Optimer inhibitor for a proprietary high-fidelity polymerase.

This partnership strategically combines Twist Bioscience's expertise in synthetic biology and genomics with Aptamer's pioneering Optimer® binder technology to create solutions for the rapidly expanding next-generation sequencing market.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are delighted to play a small but significant part in Twist Bioscience bringing the TrueAmp Library Preparation Kit to market. This product launch demonstrates the real-world value of our Optimer® technology in enabling market-ready products.

In this hot-start PCR application, the Optimer® binder demonstrates robust performance, eliminating the need for two separate antibody reagents typically required in alternative methods. We look forward to the continued success of our collaboration with Twist Bioscience and the transformative impact this product will have in advancing genomics research and clinical applications."

1. [TrueAmp Library Preparation Kit](#)
1. [Twist Bioscience Launches Next Generation Library Preparation Kits Powered by Proprietary Enzymes](#)
2. [Aptamer signs licensing agreement with Twist Bioscience](#)

- Ends -

For further information, please contact:

Aptamer Group plc	+44 (0) 1904 217 404
Dr Arron Tolley, Chief Executive Officer	
SPARK Advisory Partners Limited - Nominated Adviser	+44 (0) 20 3368 3550
Andrew Emmott	
Turner Pope Investments (TPI) Limited - Broker	+44 (0) 20 3657 0050
Andrew Thacker / Guy McDougall	
Northstar Communications Limited - Investor Relations	+44 (0) 113 730 3896
Sarah Hollins	

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders for the life sciences industry. The Group develops Optimer® binders, advanced molecules that act like antibodies by binding to specific targets. These binders are used in medicine, diagnostic tests, and research tools, offering benefits such as high stability, reliable performance, and lower costs compared with traditional antibodies.

Aptamer operates a fee-for-service business in the global market for antibody alternatives, working with leading pharmaceutical and life science companies, including all of the top 10 global pharmaceutical companies. It is also building a portfolio of Optimer® assets with partners, aiming to generate future licensing and royalty revenues.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PRLDXGDDSSBDGLG